All The Claims

1. A wireless power transmitter comprising:
a standard resonator including a standard inductor and a standard capacitor connected to the standard inductor in parallel;
one or more dedicated variable inductors connected to the standard resonator in series and having inductance varied in response to a control voltage respectively applied to the dedicated variable inductors;
one or more dedicated resonance capacitors connected to the dedicated variable inductors in parallel, respectively; and
a controlling unit outputting the control voltage.
2. The wireless power transmitter of claim 1, further comprising:
a power source unit converting input power into supply power and outputting the supply power; and
a first switch and a second switch connected to each other in series between a terminal to which the supply power is applied and a ground,
wherein the standard inductor and the dedicated variable inductors are connected between a terminal to which the first switch and the second switch are connected and the ground.
3. The wireless power transmitter of claim 2, wherein the controlling unit additionally outputs control signals controlling the first switch and the second switch, and the first switch and the second switch complementarily perform a switching on or off operation.
4. The wireless power transmitter of claim 1, wherein each of the dedicated variable inductors includes:
a primary coil; and
a secondary coil which is magnetically coupled to the primary coil and to which the control voltage is applied, and
the primary coils of the one or more dedicated variable inductors are connected to the standard inductor in series.
5. The wireless power transmitter of claim 1, wherein when the wireless power transmitter wirelessly transmits power having a common resonance frequency, the controlling unit outputs the control voltage so that levels of inductance of each of the dedicated variable inductors are reduced to zero.
6. The wireless power transmitter of claim 1, wherein when the wireless power transmitter wirelessly transmits power having a separate resonance frequency, the controlling unit outputs the control voltages so that inductances of the remaining dedicated variable inductors except for one dedicated variable inductor among the dedicated variable inductors become all zero.
7. The wireless power transmitter of claim 1, wherein the controlling unit outputs the control voltages according to a resonance frequency of a wireless power receiver which is authenticated.
8. The wireless power transmitter of claim 7, wherein when a first wireless power receiver having a first separate resonance frequency and a second wireless power receiver having a second separate resonance frequency are authenticated, the controlling unit outputs the control voltages so that power having the first separate resonance frequency is wirelessly transmitted for a first period of time and outputs the control voltages so that power having the second separate resonance frequency is wirelessly transmitted for a second period of time.
9. The wireless power transmitter of claim 8, wherein when the first wireless power receiver has a priority higher than a priority of the second wireless power receiver, the controlling unit sets the first period of time to be longer than the second period of time.
10. The wireless power transmitter of claim 9, wherein the controlling unit determines the priority based on at least one of a user grade, a charging degree of battery, and temperature of each of the first wireless power receiver and the second wireless power receiver.
11. A wireless power transmission system comprising:
an external server transmitting information regarding whether or not a wireless power receiver is authenticated and information regarding a resonance frequency of the wireless power receiver when the wireless power receiver is connected to the external server; and
a wireless power transmitter supporting the wireless power receiver so as to be connected to the external server and wirelessly transmitting power having the resonance frequency when the wireless power receiver is authenticated,
wherein the wireless power transmitter includes:
a standard resonator including a standard inductor and a standard capacitor connected to the standard inductor in parallel;
one or more dedicated variable inductors connected to the standard resonator in series and having inductance varied in response to a control voltage respectively applied to the dedicated variable inductors;
one or more dedicated resonance capacitors connected to the dedicated variable inductors in parallel, respectively; and
a controlling unit outputting the control voltage.
12. The wireless power transmission system of claim 11, wherein the wireless power transmitter includes a Wi-Fi device and the wireless power receiver is connected to the external server through the Wi-Fi device.
13. The wireless power transmission system of claim 11, wherein each of the dedicated variable inductors includes:
a primary coil; and
a secondary coil which is magnetically coupled to the primary coil and to which the control voltage is applied, and
the primary coils of the dedicated variable inductors are connected to the standard inductor in series.
14. The wireless power transmission system of claim 11, wherein when the wireless power transmitter wirelessly transmits power having a common resonance frequency, the controlling unit outputs the control voltages so that levels of inductance of each of the dedicated variable inductors are reduced to zero.
15. The wireless power transmission system of claim 11, wherein when the wireless power transmitter wirelessly transmits power having a separate resonance frequency, the controlling unit outputs the control voltage so that inductances of the remaining dedicated variable inductors except for one dedicated variable inductor among the dedicated variable inductors become all zero.
16. The wireless power transmission system of claim 11, wherein the controlling unit outputs the control voltage according to a resonance frequency of a wireless power receiver which is authenticated.
17. The wireless power transmission system of claim 16, wherein when a first wireless power receiver having a first separate resonance frequency and a second wireless power receiver having a second separate resonance frequency are authenticated, the controlling unit outputs the control voltages so that power having the first separate resonance frequency is wirelessly transmitted for a first period of time and outputs the control voltages so that power having the second separate resonance frequency is wirelessly transmitted for a second period of time.
18. The wireless power transmission system of claim 17, wherein when the first wireless power receiver has a priority higher than a priority of the second wireless power receiver, the controlling unit sets the first period of time to be longer than the second period of time.
19. The wireless power transmission system of claim 18, wherein the external server determines the priority based on at least one of a user grade, a charging degree of battery, and temperature of each of the first wireless power receiver and the second wireless power receiver and transmits information regarding the determined priority to the wireless power transmitter.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of treating cancer or other neoplasm in a subject, the method comprising steps of:
administering a therapeutically effective amount of romidepsin and a proteasome inhibitor to a subject with cancer or other neoplasm.
2. The method of claim 1, wherein romidepsin is of the formula:
3. The method of claim 1, wherein the proteasome inhibitor is selected from the group consisting of bortezomib (VELCADE\xae), peptide boronates, salinosporamide A (NPI-0052), lactacystin, epoxomicin (Ac(Me)-Ile-Ile-Thr-Leu-EX), MG-132 (Z-Leu-Leu-Leu-al), PR-171, PS-519, eponemycin, aclacinomycin A, CEP-1612, CVT-63417, PS-341 (pyrazylcarbonyl-Phe-Leu-boronate), PSI (Z-Ile-Glu(OtBu)-Ala-Leu-al), MG-262 (Z-Leu-Leu-Leu-bor), PS-273 (MNLB), omuralide (clasto-lactacystin-\u03b2-lactone), NLVS (Nip-Leu-Leu-Leu-vinyl sulfone), YLVS (Tyr-Leu-Leu-Leu-vs), dihydroeponemycin, DFLB (dansyl-Phe-Leu-boronate), ALLN (Ac-Leu-Leu-Nle-al), 3,4-dichloroisocoumarin, 4-(2-aminoethyl)-benzenesulfonyl fluoride, TMC-95A, gliotoxin, EGCG ((\u2212)-epigallocatechin-3-gallate), and YU101 (Ac-hFLFL-ex).
4. The method of claim 1, wherein the proteasome inhibitor is bortezomib (VELCADE\xae).
5-7. (canceled)
8. The method of claim 1, wherein the cancer is a malignancy of hematological cells.
9. The method of claim 1, wherein the cancer is a leukemia.
10-14. (canceled)
15. The method of claim 1, wherein the cancer is a lymphoproliferative malignancy.
16. The method of claim 1, wherein the cancer is multiple myeloma.
17. The method of claim 1, wherein the cancer is plasma cell-derived cancer.
18-20. (canceled)
21. The method of claim 1, wherein the cancer is a solid tumor.
22. (canceled)
23. The method of claim 1, wherein the cancer is a relapsed cancer.
24. The method of claim 1, wherein the cancer is a refractory cancer.
25. The method of claim 1, wherein the cancer is a bortezomib (VELCADE\xae)-resistant cancer.
26. The method of claim 1, wherein the cancer is a steroid-resistant cancer.
27. The method of claim 1, wherein the cancer is dexamethasone-resistant multiple myeloma.
28. The method of claim 1, wherein the therapeutically effective amount of romidepsin ranges from approximately 0.5 mgm2 to approximately 28 mgm2.
29. (canceled)
30. (canceled)
31. The method of claim 1, wherein the therapeutically effective amount of romidepsin ranges from approximately 8 mgm2 to approximately 14 mgm2.
32. (canceled)
33. (canceled)
34. The method of claim 1, wherein the therapeutically effective amount of romidepsin is approximately 10 mgm2.
35. (canceled)
36. (canceled)
37. The method of claim 4, wherein the therapeutically effective amount of bortezomib (VELCADE\xae) ranges from approximately 0.1 mgm2 to approximately 5 mgm2.
38-40. (canceled)
41. The method of claim 4, wherein the therapeutically effective amount of bortezomib (VELCADE\xae) ranges from approximately 0.75 mgm2 to approximately 1.5 mgm2.
42. (canceled)
43. The method of claim 4, wherein the therapeutically effective amount of bortezomib (VELCADE\xae) is approximately 1.3 mgm2.
44. The method of claim 4, wherein the therapeutically effective amount of romidepsin ranges from 4 mgm2 to 15 mgm2; and wherein the therapeutically effective amount of bortezomib (VELCADE\xae) ranges from 0.5 mgm2 to 3 mgm2.
45. (canceled)
46. (canceled)
47. The method of claim 1 further comprising administering another anti-neoplastic agent.
48. The method of claim 1 further comprising administering a cytotoxic agent.
49. The method of claim 1 further comprising administering a steroidal agent.
50. The method of claim 49, wherein the steroidal agent is selected from the group consisting of alclometasone diproprionate, amcinonide, beclomethasone diproprionate, betamethasone, betamethasone benzoate, betamethasone diproprionate, betamethasone sodium phosphate, betamethasone sodium phosphate and acetate, betamethasone valerate, clobetasol proprionate, clocortolone pivalate, cortisol (hydrocortisone), cortisol (hydrocortisone) acetate, cortisol (hydrocortisone) butyrate, cortisol (hydrocortisone) cypionate, cortisol (hydrocortisone) sodium phosphate, cortisol (hydrocortisone) sodium succinate, cortisol (hydrocortisone) valerate, cortisone acetate, desonide, desoximetasone, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, diflorasone diacetate, fludrocortisone acetate, flunisolide, fluocinolone acetonide, fluocinonide, fluorometholone, flurandrenolide, halcinonide, medrysone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, mometasone furoate, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate, prednisone, triamcinolone, triamcinolone acetonide, triamcinolone diacetate, and triamcinolone hexacetonide, and combinations thereof.
51. (canceled)
52. The method of claim 50, wherein the steroidal agent is dexamethasone.
53-54. (canceled)
55. The method of claim 52, wherein dexamethasone is administered at a dose ranging from 10 mg to 50 mg.
56. (canceled)
57. The method of claim 52, wherein dexamethasone is administered at a dose of approximately 20 mg.
58. The method of claim 1, wherein romidepsin and the proteasome inhibitor are administered intravenously.
59. (canceled)
60. The method of claim 59, wherein romidepsin is administered weekly and the proteasome inhibitor is administered twice a week.
61. (canceled)
62. The method of claim 49, wherein the steroidal agent is administered together with the romidepsin or the proteasome inhibitor.
63. The method of claim 49, wherein the steroidal agent is administered prior to or following the administration of romidepsin or the proteasome inhibitor.
64. (canceled)
65. A method of treating multiple myeloma in a subject, the method comprising steps of:
administering a therapeutically effective amount of romidepsin and bortezomib to a subject with multiple myeloma.
66. (canceled)
67. The method of claim 66, wherein the therapeutically effective amount of romidepsin ranges from 8 mgm2 to 10 mgm2.
68. The method of claim 65, wherein the therapeutically effective amount of bortezomib (VELCADE\xae) ranges from 0.5 mgm2 to 3 mgm2.
69. The method of claim 68, wherein the therapeutically effective amount of bortezomib (VELCADE\xae) is approximately 1.3 mgm2.
70. The method of claim 65, wherein the therapeutically effective amount of romidepsin ranges from 8 mgm2 to 10 mgm2; and wherein the therapeutically effective amount of bortezomib (VELCADE\xae) is approximately 1.3 mgm2.
71. The method of claim 70, wherein romidepsin is administered weekly and bortezomib (VELCADE\xae) is administered twice a week.
72. The method of claim 65, wherein the method further comprises administering a steroidal agent.
73. The method of claim 72, wherein the steroidal agent is selected from the group consisting of alclometasone diproprionate, amcinonide, beclomethasone diproprionate, betamethasone, betamethasone benzoate, betamethasone diproprionate, betamethasone sodium phosphate, betamethasone sodium phosphate and acetate, betamethasone valerate, clobetasol proprionate, clocortolone pivalate, cortisol (hydrocortisone), cortisol (hydrocortisone) acetate, cortisol (hydrocortisone) butyrate, cortisol (hydrocortisone) cypionate, cortisol (hydrocortisone) sodium phosphate, cortisol (hydrocortisone) sodium succinate, cortisol (hydrocortisone) valerate, cortisone acetate, desonide, desoximetasone, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, diflorasone diacetate, fludrocortisone acetate, flunisolide, fluocinolone acetonide, fluocinonide, fluorometholone, flurandrenolide, halcinonide, medrysone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, mometasone furoate, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone tebutate, prednisone, triamcinolone, triamcinolone acetonide, triamcinolone diacetate, and triamcinolone hexacetonide or a synthetic analog thereof, or a combination thereof.
74. (canceled)
75. The method of claim 73, wherein the steroidal agent is dexamethasone.
76-77. (canceled)
78. The method of claim 75, wherein dexamethasone is administered at a dose of approximately 20 mg.
79. (canceled)
80. The method of claim 79, wherein romidepsin is administered weekly and the bortezomib (VELCADE\xae) is administered twice a week.
81-82. (canceled)
83. The method of claim 72, wherein the steroidal agent is administered prior to or following the administration of romidepsin or the bortezomib (VELCADE\xae).
84. (canceled)
85. A method of treating cells, the method comprising steps of:
administering a combination of romidepsin and bortezomib (VELCADE\xae) to a cell.
86. The method of claim 85, wherein the step of administering comprises administering a combination of romidepsin and bortezomib (VELCADE\xae) to a cell at a concentration sufficient to kill the cell.
87-102. (canceled)
103. A method of inducing apoptosis in a cell, the method comprising:
administering an amount of romidepsin and bortezomib effective to induce apoptosis in a cell.
104-107. (canceled)
108. A pharmaceutical composition for treating cancer comprising a therapeutically effect amount of romidepsin, and a therapeutically effective amount of bortezomib.
109. (canceled)
110. (canceled)
111. The pharmaceutical composition of claim 108, wherein the cancer is multiple myeloma.
112-114. (canceled)

1. A method for hard mask layer removal, the method comprising:
dispensing a chemical on a hard mask layer, wherein the chemical comprises an acidic chemical; and
draining the chemical from a chamber,
wherein the chemical drained from the chamber is not recycled for hard mask removal.
2. The method of claim 1, wherein the chemical has a pH less than 3.
3. The method of claim 1, further comprising blending an oxidant with the acidic chemical.
4. The method of claim 1, wherein the hard mask layer is one of a metal layer, a metal oxide layer, or a metal nitride layer.
5. The method of claim 1, wherein the acidic chemical is solution-based.
6. The method of claim 1, wherein the acidic chemical is solvent-based.
7. The method of claim 1, wherein the hard mask layer is a titanium nitride layer.
8. A method for fabricating a semiconductor device, the method comprising:
providing a wafer comprising a hard mask layer;
dispensing an acidic chemical on the hard mask layer for removing the hard mask layer; and
draining the acidic chemical from a chamber,
wherein the chemical drained from the chamber is not recycled for hard mask removal.
9. The method of claim 8, wherein the hard mask layer is one of a metal layer, a metal oxide layer, or a metal nitride layer.
10. The method of claim 8, wherein the acidic chemical has a pH less than 3.
11. The method of claim 8, wherein the acidic chemical is drained from the chamber after hard mask layer removal.
12. The method of claim 8, further comprising providing an oxidant dispensing on the wafer.
13. The method of claim 12, wherein a mixture of the acidic chemical and the oxidant is drained from a chamber after hard mask layer removal.
14. The method of claim 12, wherein the acidic chemical and the oxidant are dispensed on the wafer separately.
15. The method of claim 12, wherein the acidic chemical is mixed with the oxidant, and the mixture thereof is dispensed on the wafer.
16. The method of claim 8, wherein the removing the hard mask layer by the acid chemical is spontaneous.
17. The method of claim 8, wherein the wafer comprises a dielectric layer, and the hard mask layer is formed on the dielectric layer.
18. The method of claim 8, wherein the hard mask layer is one of a titanium nitride layer, a tantalum nitride layer, or a titanium layer.
19. The method of claim 8, wherein the acidic chemical is an organic acid.
20. The method of claim 8, wherein the acidic chemical is an inorganic acid.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A clip that hooks, and thus fixes, a cover of a seat onto a frame structure, comprising:
a cover connecting portion that is integrally connected to the cover;
a hook-shaped hook portion that hooks onto, and thus fixes to, the frame structure; and
a planar covering portion that is formed in a position facing a back side portion of the hook portion,
wherein an opening that enables the back side portion of the hook portion to be visible is formed in the covering portion.
2. The clip according to claim 1, wherein the hook portion has a long shape that hooks onto, and thus fixes to, a linear hanging wire that forms the frame structure, in a state broadly engaged in a direction in which the hanging wire extends; and a through-window that is open through the hook portion and the covering portion, and in which a shape is cut out, is formed, and the opening is formed communicated with the through-window.
3. The clip according to claim 2, wherein the through-window is formed, as a cutout portion that is formed near an obstacle that impedes the hook portion from being hooked onto the hanging wire, and that avoids interference with the obstacle, in the hanging wire.
4. The clip according to claim 1, wherein the opening is formed larger than the hook shape of the hook portion.